Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Employees - 6900, CEO - Mr. Kevin T. Conroy J.D., Sector - Healthcare, Country - US, Market Cap - 8.23B

Altman ZScore(max is 10): 1.52, Piotroski Score(max is 10): 4, Working Capital: $1088389000, Total Assets: $5928139000, Retained Earnings: $0, EBIT: -1014817000, Total Liabilities: $3525890000, Revenue: $2758867000

AryaFin Target Price - $-34.56 - Current Price $44.28 - Analyst Target Price $68.96